Skip to main content
. 2017 Dec 26;9(5):6282–6297. doi: 10.18632/oncotarget.23676

Figure 4. LIMD1 interacts with TRAF6 and LMP1 in EBV latency.

Figure 4

(A) IB4 and JiJoye cell lysates were subjected to immunoprecipitation with the TRAF6 antibody clone 1H4L2 and then immunoblotting with the LIMD1 antibody clone H-4 (upper), or vice versa (bottom). (B) IB4 and JiJoye cell lysates were subjected to immunoprecipitation with the LMP1 antibody clone CS1-4 and then immunoblotting with the LIMD1 antibody H-4 (upper), or vice versa (bottom). (C) Upper panel: A diagram of the LMP1 deletion mutants for immunoprecipitation. Lower panel: 3XFlag-LMP1 and its mutants were co-transfected with pcDNA3/LIMD1 into 293T cells. After 48 h, cells were collected and cell lysates were subjected to immunoprecipitation with the LIMD1 antibody clone H-4, and immunoprecipitants were probed with the Flag antibody M2. For MG132 treatment, MG132 was added at a final concentration of 10 µM for 6 h before collection. (D) Cells were treated with MG132 at a final concentration of 10 µM for 6 h before collection. Cell lysates were subjected for IB with the indicated antibodies.